The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
A novel mechanism of action of tetracyclines: Effects on nitric oxide synthases
Open accessAbstract
Tetracyclines have recently been shown to have “chondroprotective” effects in inflammatory arthritides in animal models. Since nitric oxide (NO) is spontaneously released from human cartilage affected by osteoarthritis (OA) or rheumatoid arthritis in quantities sufficient to cause cartilage damage, we evaluated the effect of tetracyclines on the expression and function of human OA-affected nitric oxide synthase (OA-NOS) and rodent inducible NOS (iNOS). Among the tetracycline group of compounds, doxycycline > minocycline blocked and reversed both spontaneous and interleukin 1β-induced OA-NOS activity in ex vivo conditions. Similarly, minocycline ≥ doxycycline inhibited both lipopolysaccharide- and interferon-γ-stimulated iNOS in RAW 264.7 cells in vitro, as assessed by nitrite accumulation. Although both these enzyme isoforms could be inhibited by doxycycline and minocycline, their susceptibility to each of these drugs was distinct. Unlike acetylating agents or competitive inhibitors of l-arginine that directly inhibit the specific activity of NOS, doxycycline or minocycline has no significant effect on the specific activity of iNOS in cell-free extracts. The mechanism of action of these drugs on murine iNOS expression was found to be, at least in part, at the level of RNA expression and translation of the enzyme, which would account for the decreased iNOS protein and activity of the enzyme. Tetracyclines had no significant effect on the levels of mRNA for β-actin and glyceraldehyde-3-phosphate dehydrogenase nor on levels of protein of β-actin and cyclooxygenase 2 expression. These studies indicate that a novel mechanism of action of tetracyclines is to inhibit the expression of NOS. Since the overproduction of NO has been implicated in the pathogenesis of arthritis, as well as other inflammatory diseases, these observations suggest that tetracyclines should be evaluated as potential therapeutic modulators of NO for various pathological conditions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Measurement of protein using bicinchoninic acid
Smith, P. K., Krohn, R. I., Hermanson, G. T., Mallia, A. K., Gartner, F. H., Provenzano, M. D., Fujimoto, E. K., Goeke, N. M., Olson, B. J., & Klenk, D. C. (1985) · Analytical Biochemistry · doi:10.1016/0003-2697(85)90442-7 · Cited by 18,482
Role of transcription factor NF-kappa B/Rel in induction of nitric oxide synthase.
Xie, Q. W., Kashiwabara, Y., & Nathan, C. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)37600-7 · Cited by 2,212
Cited by
Wu, D. C., Jackson-Lewis, V., Vila, M., Tieu, K., Teismann, P., Vadseth, C., Choi, D.-K., Ischiropoulos, H., & Przedborski, S. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-05-01763.2002 · Cited by 1,183
Tetracyclines inhibit microglial activation and are neuroprotective in global brain ischemia
Yrjänheikki, J., Keinänen, R., Pellikka, M., Hökfelt, T., & Koistinaho, J. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.26.15769 · Cited by 1,006
Tikka, T., Fiebich, B. L., Goldsteins, G., Keinänen, R., & Koistinaho, J. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-08-02580.2001 · Cited by 958
Henry, C. J., Huang, Y., Wynne, A., Hanke, M., Himler, J., Bailey, M. T., Sheridan, J. F., & Godbout, J. P. (2008) · Journal of Neuroinflammation · doi:10.1186/1742-2094-5-15 · Cited by 678
The Promise of Minocycline in Neurology
Yong, V. W., Wells, J., Giuliani, F., Casha, S., Power, C., & Metz, L. M. (2004) · The Lancet Neurology · doi:10.1016/s1474-4422(04)00937-8 · Cited by 518
Nitric oxide and inflammatory mediators in the perpetuation of osteoarthritis
Abramson, S. B., Attur, M., Amin, A. R., & Clancy, R. (2001) · Current Rheumatology Reports · doi:10.1007/s11926-001-0069-3 · Cited by 261
Self-citationTomás-Camardiel, M., Rite, I., Herrera, A. J., de Pablos, R. M., Cano, J., Machado, A., & Venero, J. L. (2004) · Neurobiology of Disease · doi:10.1016/j.nbd.2004.01.010 · Cited by 203
Central Proinflammatory Cytokines and Pain Enhancement
Wieseler-Frank, J., Maier, S. F., & Watkins, L. R. (2005) · Neurosignals · doi:10.1159/000087655 · Cited by 198
Deleterious Effects of Minocycline in Animal Models of Parkinson’s Disease and Huntington’s Disease
Diguet, E., Fernagut, P., Wei, X., Du, Y., Rouland, R., Gross, C., Bezard, E., & Tison, F. (2004) · European Journal of Neuroscience · doi:10.1111/j.0953-816x.2004.03372.x · Cited by 189
Minocycline Enhances MPTP Toxicity to Dopaminergic Neurons
Yang, L., Sugama, S., Chirichigno, J. W., Gregorio, J., Lorenzl, S., Shin, D. H., Browne, S. E., Shimizu, Y., Joh, T. H., Beal, M. F., et al. (2003) · Journal of Neuroscience Research · doi:10.1002/jnr.10709 · Cited by 158
Clinical Potential of Minocycline for Neurodegenerative Disorders
BLUM, D., CHTARTO, A., TENENBAUM, L., BROTCHI, J., & LEVIVIER, M. (2004) · Neurobiology of Disease · doi:10.1016/j.nbd.2004.07.012 · Cited by 157
Amyotrophic Lateral Sclerosis: From Current Developments in the Laboratory to Clinical Implications
Cozzolino, M., Ferri, A., & Teresa Carrì, M. (2008) · Antioxidants & Redox Signaling · doi:10.1089/ars.2007.1760 · Cited by 156
Minocycline as Adjunctive Therapy for Schizophrenia: An Open-Label Study
Miyaoka, T., Yasukawa, R., Yasuda, H., Hayashida, M., Inagaki, T., & Horiguchi, J. (2008) · Clinical Neuropharmacology · doi:10.1097/wnf.0b013e3181593d45 · Cited by 146
Minocycline inhibits oxidative stress and decreases in vitro and in vivo ischemic neuronal damage
Morimoto, N., Shimazawa, M., Yamashima, T., Nagai, H., & Hara, H. (2005) · Brain Research · doi:10.1016/j.brainres.2005.02.062 · Cited by 137
Dewil, M., dela Cruz, V. F., Van Den Bosch, L., & Robberecht, W. (2007) · Neurobiology of Disease · doi:10.1016/j.nbd.2006.12.023 · Cited by 133
Mangat, P., Wegner, N., Venables, P. J., & Potempa, J. (2010) · Arthritis Research & Therapy · doi:10.1186/ar3000 · Cited by 111
Khodaie-Ardakani, M.-R., Mirshafiee, O., Farokhnia, M., Tajdini, M., Hosseini, S.-M.-R., Modabbernia, A., Rezaei, F., Salehi, B., Yekehtaz, H., Ashrafi, M., et al. (2014) · Psychiatry Research · doi:10.1016/j.psychres.2013.12.051 · Cited by 104
Minocycline treatment for HIV-associated cognitive impairment: Results from a randomized trial
Sacktor, N., Miyahara, S., Deng, L., Evans, S., Schifitto, G., Cohen, B. A., Paul, R., Robertson, K., Jarocki, B., Scarsi, K., et al. (2011) · Neurology · doi:10.1212/wnl.0b013e31822f0412 · Cited by 87
Lee, C. Z., Yao, J. S., Huang, Y., Zhai, W., Liu, W., Guglielmo, B. J., Lin, E., Yang, G.-Y., & Young, W. L. (2006) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/sj.jcbfm.9600268 · Cited by 78
Minocycline: a neuroprotective agent for hypoxic-ischemic brain injury in the neonate?
Buller, K. M., Carty, M. L., Reinebrant, H. E., & Wixey, J. A. (2009) · Journal of Neuroscience Research · doi:10.1002/jnr.21890 · Cited by 73
Minocycline attenuates 5-fluorouracil-induced small intestinal mucositis in mouse model
Huang, T.-Y., Chu, H.-C., Lin, Y.-L., Ho, W.-H., Hou, H.-S., Chao, Y.-C., & Liao, C.-L. (2009) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2009.09.041 · Cited by 59
Challenges of Repurposing Tetracyclines for the Treatment of Alzheimer’s and Parkinson’s Disease
Markulin, I., Matasin, M., Turk, V. E., & Salković-Petrisic, M. (2022) · Journal of Neural Transmission · doi:10.1007/s00702-021-02457-2 · Cited by 36
Determination of levels of nitric oxide in smoker and nonsmoker patients with chronic periodontitis
Wadhwa, D., Bey, A., Hasija, M., Moin, S., Kumar, A., Aman, S., & Sharma, V. K. (2013) · Journal of Periodontal & Implant Science · doi:10.5051/jpis.2013.43.5.215 · Cited by 30
Metadata
- Authors
- Amin, A. R., Attur, M. G., Thakker, G. D., Patel, P. D., Vyas, P. R., Patel, R. N., Patel, I. R., & Abramson, S. B.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 1996-11-26
- Volume
- 93
- Issue
- 24
- Pages
- 14014-14019
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2067931227
- Cited by
- 474
- References
- 2
- FWCI
- 8.25
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.